Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial
Qing Zhou(Jiangnan University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Baogang Liu(Harbin Medical University), Jun Yao(Wuhu Institute of Technology), Yanqiu Zhao(Henan Cancer Hospital), Hui Wang(Ministry of Education of the People's Republic of China), Yi Pan(Kunming Medical University), Wei Shi(Jiangsu Hengrui Medicine (China)), Xue‐Ning Yang(Guangdong Academy of Medical Sciences), Kaican Cai(Nanfang Hospital), Qingsong Pang(Chinese Academy of Medical Sciences & Peking Union Medical College), Song Li, Xianghui Du(Cancer Hospital of Chinese Academy of Medical Sciences), Baosheng Li(Guangxi Minzu University), Qifeng Wang, Yunchao Huang(North China University of Water Resources and Electric Power), Guang Han(Hubei Cancer Hospital), Qixun Chen(Chinese Academy of Sciences), Zhenfa Zhang(Tianjin Medical University Cancer Institute and Hospital), Xiao Li(Jiangsu Hengrui Medicine (China)), Weihua Yang(Shanxi Provincial Cancer Hospital)
Cited by 58
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k